why choose us

First received: September 02, 2022

Clinical Trial: Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Atrial Fibrillation Recurrent

Study Type: INTERVENTIONAL


Official Title: Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation

Brief Summary: Study name: Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation.Medicine: sacubitril/valsartan (100mg) and valsartan (80mg).Rationale: The latest guidelines represent an intensified management approach to reduce or prevent morbidity associated with atrial fibrillation.They provide stronger and more specific recommendations for catheter ablation (CA) use.However, not all patients maintain sinus rhythm after CA and…

Read more